Table 1.
Patients’ characteristics and tissue microarray expression data.
| Characteristics | N = 111 (%) |
|---|---|
| Age (years) | 66 |
| Range | 32-84 |
| Sex | |
| Male | 60 (54) |
| Female | 51 (46) |
| CEA | |
| <30 | 57 (51) |
| >30 | 41(37) |
| Unknown | 13 (12) |
| Primary tumor side | |
| Right side | 47 (43) |
| Left side | 63 (57) |
| Unknown | 1 |
| Number of metastatic sites | |
| 1 | 51 (46) |
| ≥2 | 60 (54) |
| Subsequent chemotherapy | |
| Yes | 87 (79) |
| Received aflibercept | 9/87 (10) |
| KRAS | |
| Mutant | 61 (68) |
| Wild type | 29 (32) |
| Unknown | 21 |
| NICD | |
| High | 42 (38) |
| Low | 69 (62) |
| Jag1 | |
| Positive | 68 (62) |
| Negative | 42 (38) |
| DLL4 | |
| Positive | 90 (86) |
| Negative | 14 (14) |
| Not evaluable | 7 |
| DLL3 | |
| Positive | 79 (81) |
| Negative | 18 (19) |
| Not evaluable | 14 |
| CD4/CD8 | |
| 2/1-3/1 1/1 |
84 (92) 6 (7) |
| 1/2 | 1 (1) |
| Not evaluable | 20 |
| CD3 | |
| Positive | 94 (100) |
| Negative | 0 |
| Not evaluable | 17 |
| Cyclin D1 | |
| High | 71 (75) |
| Low | 23 (25) |
| Not evaluable | 17 |
| CD44 | |
| High | 22 (24) |
| Low | 70 (76) |
| Not evaluable | 19 |
| Mismatch repair protein | |
| MSI | 7 (8) |
| MSS | 76 (92) |
| Not evaluable | 28 |
DLL, Delta-like ligand; Jag1, Jagged-1; MSI, Microsatellite instability; MSS, microsatellite stable; NICD, Notch intracellular domain.